In the meta-analysis, no reduction in morbidity or mortality benefit was found when hypertensive patients are targeted to a lower target of ≤ 135/85 mmHg as compared to a BP targets of ≤ 140-160/ 90-100 mmHg. Of note, no trials comparing different systolic BP targets were included in the analysis. Nephrology Now readers will likely be interested in reviewing the Cardio-Sis trial recently published in the Lancet which did specifically look at a strategy targeting a lower systolic blood pressure.
- Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.
- Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
- Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75Years: A Randomized Clinical Trial